small molecule

TEPMETKO

TEPOTINIB HYDROCHLORIDE

Loss of exclusivityMarch 2030latest FDA-listed patent expiry

CompanyEMD Serono →View the full company profile on CliffBio

Drug detail

Brand name	TEPMETKO
Active ingredient	TEPOTINIB HYDROCHLORIDE
Strength	EQ 225MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
8580781	March 2030	substance, product
8329692	October 2029	substance, product
8927540	July 2028	use U-3078
8658643	July 2028	use U-3077
9403799	July 2028	use U-3077
9062029	July 2028	product
8921357	May 2028	substance, product
9284300	April 2028	product

Regulatory exclusivity

Code	Expires
ODE-325	February 2028
NCE	February 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from EMD Serono